Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1992 1
1994 2
1995 2
1996 4
1997 6
1998 4
1999 4
2000 3
2001 7
2002 6
2003 5
2004 7
2005 2
2006 5
2007 6
2008 4
2009 2
2010 6
2011 6
2012 12
2013 5
2014 4
2015 8
2016 8
2017 12
2018 5
2019 6
2020 13
2021 9
2022 7
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Fuchs CS, et al. Among authors: safran h. Lancet. 2014 Jan 4;383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3. Lancet. 2014. PMID: 24094768 Clinical Trial.
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, Carneiro B, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L, Stogniew M, Allen JE, Oster W, El-Deiry WS. Prabhu VV, et al. Among authors: safran h. Neoplasia. 2020 Dec;22(12):725-744. doi: 10.1016/j.neo.2020.09.005. Epub 2020 Oct 23. Neoplasia. 2020. PMID: 33142238 Free PMC article. Review.
Clinical features of patients with MTAP-deleted bladder cancer.
De Souza AL, Mega AE, Douglass J, Olszewski AJ, Gamsiz Uzun ED, Uzun A, Chou C, Duan F, Wang J, Ali A, Golijanin DJ, Holder SL, Lagos GG, Safran H, El-Deiry WS, Carneiro BA. De Souza AL, et al. Among authors: safran h. Am J Cancer Res. 2023 Jan 15;13(1):326-339. eCollection 2023. Am J Cancer Res. 2023. PMID: 36777505 Free PMC article.
Strategies to sensitize cancer cells to immunotherapy.
George A, Sahin I, Carneiro BA, Dizon DS, Safran HP, El-Deiry WS. George A, et al. Among authors: safran hp. Hum Vaccin Immunother. 2021 Aug 3;17(8):2595-2601. doi: 10.1080/21645515.2021.1891817. Epub 2021 May 21. Hum Vaccin Immunother. 2021. PMID: 34019474 Free PMC article.
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Någård M, Ah-See ML, Strauss J, Wise-Draper T, Safran HP, Nadeau L, Edenfield WJ, Lewis LD, Ottesen LH, Li Y, Mugundu GM. Någård M, et al. Among authors: safran hp. Cancer Chemother Pharmacol. 2023 Sep;92(3):193-203. doi: 10.1007/s00280-023-04554-3. Epub 2023 Jul 2. Cancer Chemother Pharmacol. 2023. PMID: 37394627 Free PMC article. Clinical Trial.
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Carneiro BA, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma WW, Coveler AL, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weisskittel T, Li H, Borden BA, Harvey RD, Sahebjam S, Cervantes A, Koukol A, Mazar AP, Steeghs N, Kurzrock R, Giles FJ, Munster P. Carneiro BA, et al. Among authors: safran h. Clin Cancer Res. 2024 Feb 1;30(3):522-531. doi: 10.1158/1078-0432.CCR-23-1916. Clin Cancer Res. 2024. PMID: 37982822 Clinical Trial.
Combined modality therapy for pancreatic cancer.
Tsai JY, Iannitti DA, Safran H. Tsai JY, et al. Among authors: safran h. Semin Oncol. 2003 Aug;30(4 Suppl 9):71-9. doi: 10.1016/s0093-7754(03)00273-2. Semin Oncol. 2003. PMID: 12908138 Review.
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.
Safran HP, Winter K, Ilson DH, Wigle D, DiPetrillo T, Haddock MG, Hong TS, Leichman LP, Rajdev L, Resnick M, Kachnic LA, Seaward S, Mamon H, Diaz Pardo DA, Anderson CM, Shen X, Sharma AK, Katz AW, Salo J, Leonard KL, Moughan J, Crane CH. Safran HP, et al. Lancet Oncol. 2022 Feb;23(2):259-269. doi: 10.1016/S1470-2045(21)00718-X. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038433 Free PMC article. Clinical Trial.
164 results